肺癌<sup>125</sup>I粒子近距离治疗放射剂量学质量控制与保证的策略研究

李小东; 张遵城; 郑广钧; 郭永涛; 常津; 王平

doi:10.3969/j.issn.1000-8179.20140924

肺癌¹²⁵I粒子近距离治疗放射剂量学质量控制与保证的策略研究

doi: 10.3969/j.issn.1000-8179.20140924

李小东^{①, ②,},
张遵城^②,
郑广钧^③,
郭永涛^②,
常津^②,
王平^④, ,

①.
天津大学精密仪器与光电子工程学院(天津市 300072)
②.
天津医科大学第二医院放射治疗科(天津市 300211)
③.
天津医科大学第二医院胸心外科(天津市 300211)
④.
天津医科大学肿瘤医院放射治疗科(天津市 300060)

基金项目:

天津市卫生局科技基金 2010KZ100

详细信息

作者简介:
李小东主任医师, 硕士生导师。专业方向为功能影像诊断与肿瘤精确放射治疗。E-mail:lixiaodonglxd@163.com

通讯作者:
王平 wangping@timuch.com

计量
- 文章访问数: 12
- HTML全文浏览量: 1
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2014-05-31
- 修回日期: 2014-07-29
- 刊出日期: 2020-12-29

Radiation physics, quality control, and quality assurance of lung cancer brachytherapy with ¹²⁵I particles

LI Xiaodong^{①, ②
,},
ZHANG Zuncheng^②,
ZHANG Zuncheng^③,
GUO Yongtao^②,
CHANG Jin^②,
WANG Ping^{④
, ,}

①.
College of Precision Instrument and Opto-electronics Engineering, Tianjin University, Tianjin 300072, China
②.
Department of Radiation Therapy and Nuclear Medicine, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
③.
Department of Cardiathoracic Surgery, the Secord Hospital Tianjin Medical University, Tianjin 300211, China
④.
Department of Radiation Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China

Funds:

The Science and Technology Foundation of Tianjin Municipal Health Bureau 2010KZ100

More Information

Corresponding author: Ping WANG; E-mail:wangping@tjmuch.com

摘要

摘要: 目的探讨能提高125I粒子植入治疗肺癌增益比的放射物理质量控制和保证(QA/QC)的策略。方法确诊的肺癌和肺转移瘤患者287例, 男184例, 女103例, 平均年龄61.9岁。对无阻塞性肺不张非小细胞肺癌(non obstructive atelectasis non-small cell lung cancer, NOA-NSCLC)亚组和肺转移瘤组常规采用CT靶区定位, 对CT难以确定肿瘤靶区的中央型阻塞性肺不张非小细胞肺癌(the central obstructive atelectasis non-small cell lung cancer, COA-NSCLC)亚组采用符合线路单光子发射型计算机断层显像仪(single photon emission computerized tomography, SPECT)协助定位; 应用体积剂量直方图(dose volume histograms, DVH)等评估TPS的质量并优化; 影像引导粒子植入中必须进行实时的位置校正。对无法单独经皮CT引导植入粒子的晚期中央型病灶结构复杂的肺癌亚组(central lung cancer, C-LC亚组), 要同期采用纤维支气管镜(flexible fiber optic bronchoscopy, FFB)直视下联合CT引导下经皮穿刺植入; 植入后必须进行剂量学等验证。结果 137例的NOA-NSCLC亚组的计划靶区(planning target volume, PTV)外危及器官(organs at risk, OAR)心、肺及脊髓的平均照射剂量明显低于正常组织耐受剂量。NOA-NSCLC亚组和50例的肺转移瘤组的匹配周缘剂量(matched peripheral dose, MPD)分别达92.1Gy、106.2 Gy。局控总有效率分别为为91.97%(126/137例)和96.00%(48/50例)。1年生存率分别是91.24%(125/137)和83.40%(42/50)。2年生存率分别是50.36%(69/137)和52.30%(26/ 50)。COA-NSCLC亚组的35例和C-LC亚组的65例患者的局部控制总有效率分别为91.43%(32/35)和92.30%(60/65), 1年生存率分别为88.57%(31/35)和80.30%(53/66);无放射性肺损伤或肺纤维化出现。结论恰当的放射剂量学QA/QC策略是保证粒子植入疗法提高治疗增益比的必须措施, 尤其是能明显减少放射性肺炎、肺损伤或肺纤维化的发生。
- ¹²⁵I粒子 /
- 肺癌 /
- 放射剂量学 /
- 质量控制与保证 /
- 近距离治疗 /
- 肺纤维化
Abstract: Objective To improve the therapeutic gain ratio from ¹²⁵I seed implants by investigating the QA/QC strategies used in brachytherapy treatment of lung cancer. Methods A total of 287 lung cancer and pulmonary metastases cases were studied. Among which, 184 are male and 103 are female with a mean age of 61.9 years. The NOA-NSCLC subgroup and pulmonary metastases were targeted on conventional CT positioning. Considering that COA-NSCL subgroup on the tumor target area is difficult to determine with CT, the coincidence circuit SPECT was used to assist in positioning. A dose-volume histogram was constructed to evaluate the quality of the TPS and optimization. Corrections on real-time positioning are necessary when using an image-guided implantation. The C-LC should be aligned with the FFB for CT-guided percutaneous puncture implantation. After implantation, dosimetry verification was conducted. Results The NOA-NSCLC subgroup, comprising the risk organs such as heart, lung, and spinal column, received an average dose of 137, which was significantly lower than that of normal tissue dose tolerance. The NOA-NSCLC subgroup and lung metastases have matched peripheral dosages of 92.1 and 106.2 Gy with local-control efficiency rates of 91.97% (126/137) and 96.0% (48/50), 1-year survival rates of 91.24% and 83.4% (42/50), and 2-year survival rates of 50.36% (69/137) and 52.3% (26/50), respectively. The 35 COA-NSCL subgroup and 65 lung cancer group have local control efficiency rates of 91.43% (32/35) and 92.3% (60/65) and 1-year survival rates of 88.57% (31/35) and 80.30% (53/66), respectively. Conclusion Proper radiation dosimetry as a QA/QC strategy was found to improve particle-implantation therapy gain and greatly reduce the risks of radiation pneumonia and pulmonary fibrosis.
- ¹²⁵I particles /
- lung cancer /
- radiation dosimetry /
- quality control and quality assurance /
- brachytherapy /
- pulmonary fibrosis

HTML全文

表 1 靶区的放射剂量学QA/QC参数

Table 1. QA/QC parameters on radiation dosimetry of target areas

表 2 各组¹²⁵I粒子近距离治疗肺癌的疗效(%)

Table 2. ¹²⁵I seed brachytherapy treatment of lung cancer

表 3 各组不良反应治疗情况

Table 3. Efficacy and toxicity of ¹²⁵I seed brachytherapy on different groups of lung cancer cell

表 4 ¹²⁵I粒子植入疗法与其他外照射放射治疗肺损伤的对比

Table 4. Comparison of the effect of ¹²⁵I seed-implantation therapy and other external beam-radiation therapy on lung injury

参考文献(15)

[1]	邓小武.放射治疗计划设计[M]//徐向英, 曲雅勤.肿瘤放射治疗学, 第2版, 北京: 人民卫生出版社, 2013: 45-51. Deng XW, The design of the radiotherapy treatment planning.Xu Xiangying, Qu Yaqin, Editor in chief.Tumor radiation therapy, 2nd edition[M]. The second edition. Beijing: People's Medical Publishing Press, 2013:45-51.
[2]	International Atomic Energy Agency(IAEA). Calibration of brachytherapy sources[M]. IAEA TECDOC-1079, 1999, 24-28.
[3]	Lamm IL, Horton P, Lehmann W, et al. practical application of suspension criteria scenarios:radiotherapy[J]. radiation protection dosimetry, 2013, 153(2):179-184. http://cn.bing.com/academic/profile?id=4f9dd992afda36d4b5c2c088bddd343f&encoded=0&v=paper_preview&mkt=zh-cn
[4]	李小东, 李亚明.重视放射性粒子植入治疗的规范化[J].中华核医学与分子影像杂志:2013, 4(33):241-242. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhhyx201304001 Li XD, Li YM. Pay attention to the standardization of radioactive particles implantation therapy[J]. Chin J Nucl Med Mol Imaging, 2013, 4(33):241-242. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhhyx201304001
[5]	李小东.放射性粒子植入治疗[M].//李少林, 王荣福.核医学, 8版, 北京: 人民卫生出版社, 2013: 288-290. Li XD. Radioactive particles implantation therapy[M]. //Li Shao-lin, Wang Rong-fu.Nuclear medicin, The eighth edition. Beijing: People's Medical Publishing Press, 2013: 288-290.
[6]	宇传华.生存率的估计与生存曲线[M]//陈冠民.孙振球.医学统计学, 3版, 北京: 人民卫生出版社, 2011: 306-309. Yu CH, Estimates of survival rate and survival curve. Chen Guanmin, Sun Zhenqiu, Editor in chief. Medical statistics, The Third Edition[M]. Beijing: People's Medical Publishing Press, 2011: 306-309.
[7]	陈明, 蒋国梁, 朱国培.放射肿瘤学临床前瞻性随机试验的设计和实施[M]//蒋国梁.现代肿瘤放射治疗学.上海: 上海科学技术出版社, 2003: 674-731. Chen Ming, Jiang Guoliang, Zhu Guo-pen. Design and implementation of radiation oncology clinical prospective randomized trial [M].//Jiang Guoliang. Modern cancer radiation therapy[M]. Sanghai: Shanghai science and Technology Press, 2003: 674-731.
[8]	Zishan A, Mojgan T, Andrea B, et al. The Impact of Tumor Sizeon Outcomes After Stereotactic Body Radiation Therapyf or Medically Inoperable Early-StageNon-Small Cell Lung Cancer[J]. International Journal of Radiation Oncology biology physics: 2013, 5(87):1064-70. http://europepmc.org/abstract/med/24210082
[9]	马秀梅, 陈海燕, 白永瑞, 等.逆向调强放射治疗肺癌患者发生放射性肺炎相关因素分析[J].上海交通大学学报(医学版), 2013, 4(33):485-501.] http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=shdeykdxxb201304022 Ma XM, Chen HY, Bai YR, et al. Inverse intensity-modulated radiotherapy in patients with lung cancer, analyzing the relative factors of radiation pneumonitis[J]. Journal of Shanghai Jiao Tong University(Medical Science Edition). 2013, 4(33):485-501. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=shdeykdxxb201304022
[10]	Giroux Leprieura E, Fernandezc D, Chatellier G, et al. Cancers bronchiques non a petites cellules:facteurs predictifs de survenue de pneumopathie radique Non-small cell lung cancer[J]. Risk factors of radiation pneumonitis. Cancer Radiothérapie, 2012, 16(4):257-262.
[11]	Rampinelli Cl, Bellomi M, Ivaldi GB, et al. Assessment of pulmonary fibrosis after radiotherapy(RT) in breast conserving surgery: comparison between conventional external beam RT(EBRT) and intraoperative RT with electrons (ELIOT)[J]. Technol Cancer Res Treat. 2011, 10(4):323-329. doi: 10.7785/tcrt.2012.500209
[12]	曾自力, 刘兵.三维适形放疗计划轮照对肺癌剂量分布影响的研究[J].中国医学物理学杂志, 2011, 2(28):2471~2474.] http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgyxwlxzz201102005 Zeng ZL, Liu B. Study Impact of Three Dimensional Conformal Radiotherapy Plans to Take Turn Radiotherapy for Lung Cancer Dose Distribution[J]. Chin J Med Phys, 2011, 2(28):2471-2474. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgyxwlxzz201102005
[13]	廖安燕, 王俊杰.持续低剂量率照射治疗前列腺癌的生物学效应[J].国外医学·放射医学核医学分册, 2005, 7(29):190-192.] http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=gwyx-fsyxhyxfc200504014 Liao AY, Wang JJ. Biological effect of continuous low dose rate irradiation for prostate cancer[J]. Foreign Med Sci, Radiol Nuclear Med. 2005: 7(29), 190-192. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=gwyx-fsyxhyxfc200504014
[14]	Nag S, Ellis RJ, Merrick GS, et al. American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy[J]. Int J Radiat Oncol Biol Phys, 2002, 54:462-470. doi: 10.1016/S0360-3016(02)02937-1
[15]	中华人民共和国卫生部.国家职业卫生标准[M].低能γ光子粒子源植入治疗的放射防护与质量控制检测规范, GBZ178－2006. Ministry of Health of the People's Republic of China, The national health standard occupation.Radiation protection and quality control standard of low energy γ photon brachytherapy particle sources. GBZ178-2006.